Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Moderna's mRNA Flu Shot Wins US Approval in FDA Turnaround (1)

6 August 2026 · By · Wire by Fusion42

Published

6 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at news.bloomberglaw.com →

◆ Verified

Fusion42 · 30 August 2026 · Fusion42 review

Moderna received FDA approval for its mRNA-based flu vaccine, mFlusiva, for adults aged 50 and over, with traditional and accelerated approval pathways depending on age.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 6 Aug 2026 and 8 Aug 2026.

◆ ◆ The Wire takeaway

Your prospects in mRNA vaccines just broadened beyond Covid with FDA approval in flu shots, making vaccines a more diverse growth area than before. Expect competition and demand for mRNA formulation expertise to rise sharply.

◆ Coverage

4 sources · first reported 6 Aug 2026 · latest 8 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalmRNA-vaccineflu-shotmodernapharma-regulation